Immune Therapeutics Inc (IMUN):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Immune Therapeutics Inc (IMUN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9364)・商品コード:DATA904C9364
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:22
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Immune Therapeutics Inc (IMUN), formerly pH Environmental Inc, is a specialty pharmaceutical company that discovers, develops and commercializes patented therapies and technology such as Lodonal, LDN, CAR-T and MENK. The company’s patented therapies are focused on the activation and re-balancing and stimulating the body’s immune system. Its patented therapies are used in the treatment of cancers, HIV, autoimmune diseases, inflammatory conditions and other chronic infectious diseases. IMUN offers Lodonal trials, an immune system regulator in the management of HIV patients; International Immunopharmacology, a low-dose naltrexone (LDN): a promising treatment in immune-related diseases and cancer therapies and clinical trials. The company’s projects are conducted in Kenya, China and Africa. IMUN is headquartered in Orlando, Florida, the US.

Immune Therapeutics Inc (IMUN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immune Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Immune Therapeutics to Enter into Distribution Agreement with GB Pharma and Rougier Pharma Afrique 10
Fidson Healthcare Partners with Immune Therapeutics, GB Pharma and AHAR 11
Licensing Agreements 12
TNI BioTech Enters into Licensing Agreement 12
Immune Therapeutics Signs Licensing Agreement with Super-T Cell Cancer 13
Equity Offering 14
Immune Therapeutics to Raise Funds in Private Placement of Shares 14
Immune Therapeutics Raises USD0.2 Million in Private Placement of Shares 15
Acquisition 16
pH Environmental Acquires TNI BioTech IP 16
Immune Therapeutics Inc – Key Competitors 17
Immune Therapeutics Inc – Key Employees 18
Immune Therapeutics Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Aug 23, 2018: Immune Therapeutics names Dr. Gary Blick to advisory board 20
Aug 23, 2017: Immune Therapeutics Appoints John H. Abeles, M.D. as Chairman and CEO of Company’s Subsidiary, Cytocom and as Senior Adviser to Immune Therapeutics 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immune Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immune Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Immune Therapeutics to Enter into Distribution Agreement with GB Pharma and Rougier Pharma Afrique 10
Fidson Healthcare Partners with Immune Therapeutics, GB Pharma and AHAR 11
TNI BioTech Enters into Licensing Agreement 12
Immune Therapeutics Signs Licensing Agreement with Super-T Cell Cancer 13
Immune Therapeutics to Raise Funds in Private Placement of Shares 14
Immune Therapeutics Raises USD0.2 Million in Private Placement of Shares 15
pH Environmental Acquires TNI BioTech IP 16
Immune Therapeutics Inc, Key Competitors 17
Immune Therapeutics Inc, Key Employees 18

List of Figures
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Immune Therapeutics Inc (IMUN):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9364)販売に関する免責事項を必ずご確認ください。
★調査レポート[Immune Therapeutics Inc (IMUN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆